Therapeutic drug monitoring of indinavir in HIV-infected patients undergoing HAART
| Autor: | Michael Zilly, Benedikt Weissbrich, Hartwig Klinker, Desch S, P Langmann, T Väth |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Microbiology (medical)
medicine.medical_specialty Dose medicine.medical_treatment HIV Infections Indinavir Pharmacology Gastroenterology Internal medicine Antiretroviral Therapy Highly Active Blood plasma Medicine Humans Dosing Sida Chromatography High Pressure Liquid Retrospective Studies Chemotherapy Ritonavir biology medicine.diagnostic_test business.industry General Medicine HIV Protease Inhibitors biology.organism_classification Infectious Diseases Therapeutic drug monitoring HIV-1 Patient Compliance Drug Monitoring business medicine.drug |
| Zdroj: | Infection. 30(1) |
| ISSN: | 0300-8126 |
| Popis: | Background: Therapeutic drug monitoring (TDM) of protease inhibitors (PI) is gaining increasing importance for the management of HIV-infected patients undergoing highly active antiretroviral therapy (HAART). The PI indinavir (IDV) is widely used in HAART regimens. Combinations of IDV with ritonavir (RTV) have been used to increase the plasma concentration of IDV. However, the desirable IDV concentration range in clinical practice remains to be elucidated. Patients and Methods: To study the value of TDM for IDV in clinical practice, a retrospective analysis of 501 plasma samples of patients treated with IDV in various dosages was performed. IDV levels were determined during routine outpatient visits. Analysis was performed by high pressure liquid chromatography (HPLC) with UV detection. Results: A widespread range of IDV plasma concentrations was seen both within and between patients. The mean IDV level during therapy with IDV 2.4 g/d was 3,260 ng/ml (95% CI: 2,903 ng/ml; 3,618 ng/ml). IDV levels at a dose of IDV 1.6 g/d in combination with RTV resulted in a mean IDV plasma concentration of 4,191 ng/ml (95% CI: 3,356 ng/ml; 5,016 ng/ml). There was no significant difference between plasma levels at the doses of 2.4 g/d and 1.6 g/d. 35 of all 130 patients treated with IDV reached only suboptimal IDV plasma concentrations below the limit of 150 ng/ml. There was no statistically significant difference between the number of patients below an IDV plasma concentration of 150 ng/ml in the various dosage regimens. Conclusion: During therapy with IDV in a b.i.d. scheme, similar IDV plasma concentrations and a comparable number of patients with subinhibitory plasma concentrations were observed when compared to a therapeutic regimen with t.i.d. dosing. In this study, even at various times of plasma sampling after oral ingestion, TCM facilitated the surveillance of patients compliance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink